Oncology & Cancer

Patient preferences explored in multiple myeloma treatment

(HealthDay)—An Eastern Cooperative Oncology Group (ECOG) performance status of ≥2 is linked to lower treatment satisfaction in patients with relapsed or refractory multiple myeloma (RRMM), but receiving medication orally ...

Oncology & Cancer

MGUS can progress to multiple myeloma within five years

(HealthDay)—Individuals with low- or intermediate-risk monoclonal gammopathy of undetermined significance (MGUS) can experience progression to multiple myeloma within five years, according to a study published online July ...

Medications

Daratumumab cuts risk for progression in multiple myeloma

(HealthDay)—For patients with newly diagnosed multiple myeloma, the addition of daratumumab to lenalidomide and dexamethasone is associated with a reduced risk for disease progression or death, according to a study published ...

Oncology & Cancer

Addition of elotuzumab ups PFS in refractory multiple myeloma

(HealthDay)—For patients with multiple myeloma in whom treatment with lenalidomide and a proteasome inhibitor has failed, progression-free survival (PFS) is longer in those receiving the immunostimulatory monoclonal antibody ...

page 1 from 23

Multiple myeloma

Multiple myeloma (from myelo-, bone marrow), also known as MM, myeloma, plasma cell myeloma, or as Kahler's disease (after Otto Kahler) is a cancer of the white blood cells known as plasma cells, which produce antibodies.

These plasma cells, or B cells, are part of the immune system, formed in bone marrow, and numerous in lymphatics. Myeloma is incurable, but remissions may be induced with steroids, chemotherapy, thalidomide and stem cell transplants.

There were 15,270 cases diagnosed and 11,070 deaths in the United States in 2004, and an incidence of 4/100,000 worldwide. Median survival is 50–55 months. Chromosome diagnosis can separate patients into more or less favorable prognoses.

Myeloma is part of the broad group of diseases called hematological malignancies.

This text uses material from Wikipedia, licensed under CC BY-SA